The antiviral activity of antibodies in vitro and in vivo

Advances in Immunology

Volumn 77, Issue , 2001, Pages 195-262

  Parren, Paul W H I ^a   Burton, Dennis R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; VIRUS ANTIBODY;

ANIMAL; CYTOTOXICITY; HUMAN; IMMUNOLOGY; INTRACELLULAR FLUID; PHAGOCYTOSIS; REVIEW; SERODIAGNOSIS; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTRACELLULAR FLUID; NEUTRALIZATION TESTS; PHAGOCYTOSIS; VIRUS DISEASES;

EID: 0035222608     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(01)77018-6     Document Type: Article

References (259)

1. Arthos, J., Deen, K. C., Chaikin, M. A., Fornwald, J. A., Sathe, G., Sattentau, Q. J., Clapham, P. R., Weiss, R. A., McDougal, J. S., Pietropaolo, C., Axel, R., Truneh, A., Maddon, P. J., and Sweet, R. W. (1989). Identification of the residues in human CD4 critical for the binding of HIV. Cell 57, 469-481.
2. Arthur, L. O., Bess, J. W., Jr., Sowder, R. C. II, Benveniste, R. E., Mann, D. L., Chermann, J.-C., and Henderson, L. E. (1992). Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science 258, 1935-1938.
3. Arthur, L. O., Bess, J. W., Jr., Urban, R. G., Strominger, J. L., Morton, W. R., Mann, D. L., Henderson, L. E., and Benveniste, R. E. (1995). Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J. Virol. 69, 3117-3124.
4. Ashe, W. K., and Notkins, A. L. (1967). Kinetics of sensitization of herpes simplex virus and its relationship to the reduction in the neutralization rate constant. Virology 33, 613-617.
5. Ashe, W. K., Mage, M., and Notkins, A. L. (1969). Kinetics of neutralization of sensitized herpes simplex virus with antibody fragments. Virology 37, 290-293.
6. Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H., Stiegler, G., Bernacky, B. J., Rizvi, T. A., Schmidt, R., Hill, L. R., Keeling, M. E., Lu, Y., Wright, J. E., Chou, T.-C., and Ruprecht, R. M. (2000). Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206.
7. Bachmann, M. F., Kalinke, U., Althage, A., Freer, G., Burkhart, C., Roost, H.-P., Aguet, M., Hengartner, H., and Zinkernagel, R. M. (1997). The role of antibody concentration and avidity in antiviral protection. Science 276, 2024-2027.
8. Balachandran, N., Bacchetti, S., and Rawls, W. E. (1982). Protection against lethal challenge of balb/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex type 2. Infect. Immun. 37, 1132-1137.
9. Baldridge, J. R., and Buchmeier, M. J. (1992). Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: Mother-to-baby transfer of humoral protection. J. Virol. 66, 4252-4257.
10. Bedinger, P., Moriarty, A., von Borstel, R. C., Donovan, N. J., Steimer, K. S., and Littman, D. R. (1988). Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature 334, 162-165.
11. Beijerinck, M. W. (1898). Over een Contagium vivum fluidum als oorzaak van de vlekziekte der tabaksbladen. Versl. Gew. Verg. Wis en Natuurk. Afd., Kon. Acad. Wetensch. Amsterdam VII, 229-235.
12. Belnap, D. M., McDermott, B. M., Jr., Filman, D. J., Cheng, N., Trus, B. L., Zuccola, H. J., Racaniello, V. R., Hogle, J. M., and Steven, A. C. (2000). Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl. Acad. Sci. 97, 73-78.
13. Berger, E. A. (1997). HIV entry and tropism: The chemokine receptor connection. AIDS 11 (Suppl A), S3-S16.
14. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000). The protein data bank. Nucleic Acids Res. 28, 235-242.
15. Binley, J. M., Clas, B., Gettie, A., Vesanen, M., Montefiori, D. C., Sawyer, L., Booth, J., Lewis, M., Marx, P. A., Bonhoeffer, S., and Moore, J. P. (2000). Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology 270, 237-249.
16. Blasco, R., and Moss, B. (1992). Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J. Virol. 66, 4170-4179.
17. Blondel, B., Crainic, R., Fichot, O., Dufraisse, G., Candrea, A., Diamond, D., Girard, M., and Horaud, F. (1986). Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J. Virol. 57, 81-90.
18. Boere, W. A. M., Benaissa-Trouw, B. J., Harmsen, T., Erich, T., Kraaijeveld, C. A., and Snippe, H. (1985). Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. J. Virol. 54, 546-551.
19. Bomsel, M., Heyman, M., Hocini, H., Lagaye, S., Belec, L., Dupont, C., and Desgranges, C. (1998). Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dlgA or IgM. Immunity 9, 277-287.
20. Booy, F. P., Roden, R. B. S., Greenstone, H. L., Schiller, J. T., and Trus, B. L. (1998). Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 Å resolution. J. Mol. Biol. 281, 95-106.
21. Boyer, V., Delibrias, C., Noraz, N., Fischer, F., Kazatchkine, M. D., and Desgranges, C. (1992). Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scand. J. Immunol. 36, 879-883.
22. Brioen, P., Thomas, A. A. M., and Boeye, A. (1985). Lack of quantitative correlation between the neutralization of poliovirus and the antibody-mediated pI shift of the virions. J. Gen. Virol. 66, 609-613.
23. Britt, W. J., and Chesebro, B. (1983). Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J. Immunol. 130, 2363-2367.
24. Buchmeier, M. J., Lewicki, H. A., Talbot, P. J., and Knobler, R. L. (1984). Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody. Virology 132, 261-270.
25. Burnet, F. M., Keogh, E. V., and Lush, D. (1937). The immunological reactions of the filterable viruses. Austral. J. Exp. Biol. Med. Sci. 15, 227-368.
26. Burns, J. W., Siadat-Pajouh, M., Krishnaney, A. A., and Greenberg, H. G. (1996). Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272, 104-107.
27. Burton, D. R., and Barbas, C. F. (1994). Human antibodies from combinatorial libraries. Adv. Immunol. 57, 191-280.
28. Burton, D. R., and Parren, P. W. H. I. (2000). Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection? Nat. Med. 6, 123-125.
29. Burton, D. R., Williamson, R. A., and Parren, P. W. H. I. (2000). Antibody and virus: Binding and neutralization. Virology 270, 1-3.
30. Burton, D. R., and Woof, J. M. (1992). Human antibody effector function. Adv. Immunol. 51, 1-84.
31. Capobianchi, M. R., Fais, S., Castilletti, C., Gentile, M., Ameglio, F., and Dianzani, F. (1994). A simple and reliable method to detect cell membrane proteins on infectious human immunodeficiency virus type 1 particles. J. Infect. Dis. 169, 886-889.
32. Chanock, R. M., Crowe, J. E., Jr., Murphy, B. R., and Burton, D. R. (1993). Human monoclonal antibody Fab fragments cloned from combinatorial libraries: Potential usefulness in prevention and/or treatment of major human viral diseases. Infect. Agents Dis. 2, 118-131.
33. Che, Z., Olson, N. H., Leippe, D., Lee, W.-M., Mosser, A. G., Rueckert, R. R., Baker, T. S., and Smith, T. J. (1998). Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J. Virol. 72, 4610-4622.
34. Chen, Z., Li, K., Rowland, R. R., and Plagemann, P. G. (1999). Selective antibody neutralization prevents neuropathogenic lactate dehydrogenase-elevating virus from causing paralytic disease in immunocompetent mice. J. Neurovirol. 5, 200-208.
35. Chesebro, B., Wehrly, K., Doig, D., and Nishio, J. (1979). Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: Influnce of the Rfv-3 gene. Proc. Natl. Acad. Sci. USA 76, 5784-5788.
36. Collins, J. J., Sackie, D. M., and Johnson, G. R. (1983). Immunotherapy of murine leukemia. IX. The requirement for the Fc portion of antibody for successful passive serum therapy of Friend leukemia virus-induced disease. Virology 126, 259-266.
37. Colonno, R. J., Callahan, P. L., Leippe, D. M., Rueckert, R. R., and Tomassini, J. E. (1989). Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J. Virol. 63, 36-42.
38. Connor, R. I., Dinces, N. B., Howell, A. L., Romet-Lemonne, J.-L., Pasquali, J.-L., and Fanger, M. W. (1991). Fc receptors for IgG (FcγRs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): Studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the FcγR. Proc. Natl. Acad. Sci. USA 88, 9593-9597.
39. Corbeil, S., Seguin, C., and Trudel, M. (1996). Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. Vaccine 14, 521-525.
40. Corbin, A., Prats, A. C., Darlix, J. L., and Sitbon, M. (1994). A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses. J. Virol. 68, 3857-3867.
41. Crainic, R., Couillin, P., Blondel, B., Cabau, N., Boue, A., and Horodniceanu, F. (1983). Natural variation of poliovirus neutralization epitopes. Infect. Immun. 41, 1217-1225.
42. Crowe, J. E., Jr., Murphy, B. R., Chanock, R. M., Williamson, R. A., Barbas, C. F., and Burton, D. R. (1994). Human RSV monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc. Natl. Acad. Sci. USA 91, 1386-1390.
43. Dalziel, R. G., Lampert, P. W., Talbot, P. J., and Buchmeier, M. J. (1986). Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence. J. Virol. 59, 463-471.
44. Daniels, C. A. (1975). Mechanisms of viral neutralization. In Viral Immunology and Immunopathology. New York: Academic Press, pp. 79-97.
45. Della-Porte, A. J., and Westaway, E. G. (1977). A multi-hit model for the neutralization of animal viruses. J. Gen. Virol. 38, 1-19.
46. Diamond, D. C., Jameson, B. A., Bonin, J., Kohara, M., Abe, S., Itoh, H., Komatsu, T., Arita, M., Kuge, S., Nomoto, A., Osterhaus, A. D. M. E., Crainic, R., and Wimmer, E. (1985). Antigenic variation and resistance to neutralization in poliovirus Type 1. Science 229, 1090-1093.
47. Dietzschold, B., Kao, M., Zhen, Y. M., Chen, Z. Y., Maul, G., Fu, Z. F., Rupprecht, C. E., and Koprowski, H. (1992). Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc. Natl. Acad. Sci. USA 89, 7252-7256.
48. Dimmock, N. J. (1993). Neutralization of animal viruses. Curr. Top. Microbiol. Immunol. 183, 1-149.
49. Dimmock, N. J. (1995). Update on the neutralization of animal viruses. Rev. Med. Virol. 5, 165-179.
50. Dittmer, U., Brooks, D. M., and Hasenkrug, K. J. (1998). Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J. Virol. 72, 6554-6558.
51. Dittmer, U., Brooks, D. M., and Hasenkrug, K. J. (1999a). Requirement for multiple lymphocyte subsets in protection by a live-attenuated vaccine against retroviral infection. Nat. Med. 5, 189-193.
52. Dittmer, U., Race, B., and Hasenkrug, K. J. (1999b). Kinetics of the development of protective immunity in mice vaccinated with a live-attenuated retrovirus. J. Virol. 73, 8435-8440.
53. Dix, R. D., Pereira, L., and Baringer, J. R. (1981). Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect. Immun. 34, 192-199.
54. Dubay, J. W., Dubay, S. R., Shin, H.-J., and Hunter, E. (1995). Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: Requirement of precursor cleavage for glycoprotein incorporation. J. Virol. 69, 4675-4682.
55. Dulbecco, R., Vogt, M., and Strickland, A. G. R. (1956). A study of the basic aspects of neutralization of two animal viruses, Western equine encephalitis virus and poliomyelitis virus. Virology 2, 162-205.
56. Emini, E. A., Kao, S.-Y., Lewis, A. J., Crainic, R., and Wimmer, E. (1983a). Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies. J. Virol. 46, 466-474.
57. Emini, E. A., Ostapchuk, P., and Wimmer, E. (1983b). Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization. J. Virol. 48, 547-550.
58. Engelstad, M., Howard, S. T., and Smith, G. L. (1992). A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188, 801-810.
59. Fazekas de St.Groth, S. (1962). The neutralization of viruses. Adv. Virus Res. 9, 1-125.
60. Fischer, R., Liao, Y. C., Hoffman, K., Schillberg, S., and Emans, N. (1999). Molecular farming of recombinant antibodies in plants. Biol. Chem. 380, 825-839.
61. Flamand, A., Raux, H., Gandin, Y., and Ruigrok, R. W. (1993). Mechanisms of rabies virus neutralization. Virology 194, 302-313.
62. Flynn, D. C., Olmsted, R. A., Mackenzie, J. M. J., and Johnston, R. E. (1988). Antibody-mediated activation of Sindbis virus. Virology 166, 82-90.
63. Fodor, W. L., Rollins, S. A., Bianco-Caron, S., Rother, R. P., Guilmette, E. R., Burton, W. V., Albrecht, J. C., Fleckenstein, B., and Squinto, S. P. (1995). The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J. Virol. 69, 3889-3892.
64. Forthal, D. N., Landucci, G., Katz, J., and Tilles, J. G. (1993). Comparison of measles virus-specific antibodies with antibody-dependent cellular cytotoxicity and neutralizing functions. J. Infect. Dis. 168, 1020-1023.
65. Fujinami, R. S., and Oldstone, M. B. (1980). Alterations in expression of measles virus polypeptides by antibody: Molecular events in antibody-induced antigenic modulation. J. Immunol. 125, 78-85.
66. Fujinami, R. S., and Oldstone, M. B. A. (1979). Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature 279, 529-530.
67. Fujinami, R. S., Rosenthal, A., Lampert, P. W., Zurbriggen, A., and Yamada, M. (1989). Survival of athymic (nu/nu) mice after Theiler's murine encephalomyelitis virus infection by passive administration of neutralizing monoclonal antibody. J. Virol. 63, 2081-2087.
68. Fujioka, H., Emancipator, S. N., Aikawa, M., Huang, D. S., Blatnik, F., Karban, T., DeFife, J., and Manzanec, M. B. (1998). Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. J. Exp. Med. 188, 1223-1229.
69. Gauduin, M.-C., Parren, P. W. H. I., Weir, R., Barbas, C. F., Burton, D. R., and Koup, R. A. (1997). Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Med. 3, 1389-1393.
70. Gelderblom, H., Reupke, H., Winkel, T., Kunze, R., and Pauli, G. (1987). MHC-antigens: Constituents of the envelopes of human and simian immunodeficiency viruses. Z. Naturforsch 42c, 1328-1334.
71. Gelderblom, H. R. (1991). Assembly and morphology of HIV: Potential effect of structure on viral function. AIDS 5, 617-637.
72. Gould, E. A., Buckley, A., Barrett, A. D., and Cammack, N. (1986). Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67, 591-595.
73. Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., Mendez, M. J., Abderrahim, H., Noguchi, M., Smith, D. H., Zeng, Y., David, N. E., Sasai, H., Garza, D., Brenner, D. G., Hales, J. F., McGuinness, R. P., Capon, D. J., Klapholz, S., and Jakobovits, A. (1994). Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nature Genetics 7, 13-21.
74. Halstead, S. B. (1979). In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140, 527-533.
75. Halstead, S. B. (1982). Immune enhancement of viral infection. Progr. Allergy 31, 301-364.
76. Harris, L. J., Larson, S. B., Hasel, K. W., and McPherson, A. (1997). Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36, 1581-1597.
77. Hasenkrug, K. J., Brooks, D. M., and Chesebro, B. (1995). Passive immunotherapy for retroviral disease: Influence of major histocompatibility complex type and T-cell responsiveness. Proc. Natl. Acad. Sci. USA 92, 10492-10495.
78. Hawkes, R. A., and Lafferty, K. J. (1967). The enhancement of virus infectivity by antibody. Virology 33, 250-261.
79. Hayashida, I., Nagafuchi, S., Hayashi, Y., Kino, Y., Mori, R., Oda, H., Ohtomo, N., and Tashiro, A. (1982). Mechanism of antibody-mediated protection against herpes simplex virus infection in athymic nude mice: Requirement of Fc portion of antibody. Microbiol. Immunol. 26, 497-509.
80. He, Y., Bowman, V. D., Mueller, S., Bator, C. M., Bella, J., Peng, X., Baker, T. S., Wimmer, E., Kuhn, R. J., and Rossman, M. G. (2000). Interaction of the poliovirus receptor with poliovirus. Proc. Natl. Acad. Sci. USA 97, 79-84.
81. Healey, D., Dianda, L., Moore, J. P., McDougal, J. S., Moore, M. J., Estess, P., Buck, D., Kwong, P. D., Beverley, P. C., and Sattentau, Q. J. (1990). Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J. Exp. Med. 172, 1233-1242.
82. Heath, A. W., Martins, M. S., and Hudson, L. (1990). Monoclonal antibodies mediating viable immunofluorescence and protection against Trypanosoma cruzi infection. Trop. Med. Parasitol. 41, 425-428.
83. Hemming, V. G., Prince, G. A., Horswood, R. L., London, W. T., Murphy, B. R., Walsh, E. E., Fischer, G. W., Weisman, L. E., Baron, P. A., and Chanock, R. M. (1985). Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J. Infect. Dis. 152, 1083-1087.
84. Hewat, E., and Blaas, D. (1996). Structure of a neutralizing antibody bound bivalently to human rhinovirus 2. EMBO J. 15, 1515-1523.
85. Hewat, E., and Blaas, D. (2001). Structural studies on antibody interacting with viruses. Curr. Top. Microbiol. Immunol. (in press)
86. Homsy, J., Meyer, M., Tateno, M., Clarkson, S., and Levy, J. (1989). The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244, 1357-1360.
87. Hooks, J. J., Burns, W., Hayashi, K., Geis, S., and Notkins, A. L. (1976). Viral spread in the presence of neutralization antibody: Mechanisms of persistence in foamy virus infection. Infect. Immun. 14, 1172-1178.
88. Hoxie, J. A., Fitzharris, T. P., Youngbar, P. R., Matthews, D. M., Rackowski, J. L., and Radka, S. F. (1987). Nonrandom association of cellular antigens with HTLV-III virions. Hum. Immunol. 18, 39-52.
89. Icenogle, J., Shiwen, H., Duke, G., Gilbert, S., Rueckert, R., and Anderegg, J. (1983). Neutralization of poliovirus by a monoclonal antibody: Kinetics and stoichiometry. Virology 127, 412-425.
90. Ichihashi, Y. (1996). Extracellular enveloped vaccinia virus escapes neutralization. Virology 217, 478-485.
91. Iorio, R. M., and Bratt, M. A. (1983). Monoclonal antibodies to newcastle disease virus: Delineation of four epitopes on the HN Glycoprotein. J. Virol. 48, 440-450.
92. Iorio, R. M., and Bratt, M. A. (1984). Neutralization of Newcastle disease virus by monoclonal antibodies to the Hemagglutinin-Neuraminidase Glycoprotein: Requirement for antibodies to four sites for complete neutralization. J. Virol. 51, 445-451.
93. Isaacs, S., Wolffe, E. J., Payne, L. G., and Moss, B. (1992). Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J. Virol. 66, 7217-7224.
94. Ishizaka, S. T., Piacente, P., Silva, J., and Mishkin, E. M. (1995). IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J. Infect. Dis. 172, 1108-1111.
95. Jerne, N. K., and Avegno, P. (1956). The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: Reversible and irreversible inactivation. J. Immunol. 76, 200-208.
96. Johnson, S., Griego, S. D., Pfarr, D. S., Doyle, M. L., Woods, R., Carlin, D., Prince, G. A., Koenig, S., Young, J. F., and Dillon, S. B. (1999). A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J. Infect. Dis. 180, 35-40.
97. Karlsson, G. B., Gao, F., Robinson, J., Hahn, B., and Sodroski, J. (1996). Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J. Virol. 70, 6136-6142.
98. Kato, H., Kato, R., Fujihashi, K., and McGhee, J. R. (2000). Role of mucosal antibodies in viral infections. Curr. Top. Microbiol. Immunol. (in press).
99. Kilbourne, E. D., Laver, W. G., Schulman, J. L., and Webster, R. G. (1968). Antiviral activity of antiserum specific for an influeza virus neuraminidase. J. Virol. 2, 281-288.
100. Kimura, Y. (1973). Phenotypic mixing of vesicular stomatitis virus with HVJ (Sendai Virus). Japan. J. Microbiol. 17, 373-381.
101. Kingsford, L. (1984). Enhanced neutralization of La Crosse Virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoprotein. Virology 136, 265-273.
102. Klasse, P. J., and Moore, J. P. (1996). Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J. Virol. 70, 3668-3677.
103. Kotwal, G. J., Isaacs, S. N., McKenzie, R., Frank, M. M., and Moss, B. (1990). Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250, 827-830.
104. Kreil, T. R., and Eibl, M. M. (1997). Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J. Virol. 71, 2921-2927.
105. Krummel, W. M., and Uhr, J. W. (1969). A mathematical and experimental study of the kinetics of neutralization of bacteriophage φX 174 by antibodies. J. Immunol. 102, 772-785.
106. Lafferty, K. J. (1963a). The interaction between virus and antibody. Virology 21, 61-75.
107. Lafferty, K. J. (1963b). The interaction between virus and antibody II. Mechanism of the reaction. Virology 21, 76-90.
108. Lamarre, A., and Talbot, P. J. (1995). Protection from lethal coronavirus infection by immunoglobulin fragments. J. Immunol. 154, 3975-3984.
109. Lamarre, A., Yu, M. W., Chagnon, F., and Talbot, P. J. (1997). A recombinant single chain antibody neutralizes corona virus infectivity but only slightly delays lethal infection of mice. Eur. J. Immunol. 27, 3447-3455.
110. Lamb, R. A., and Krug, R. M. (1996). Orthomyxoviridiae: The viruses and their replication. In Fields Virology (Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., Melnick, J. L., Monath, T. P., Roizman, B., and Straus, S. E., Eds.). Philadelphia, PA: Lippincott-Raven Publishers), pp. 1353-1395.
111. Lamon, E. W., Powell, T. J., Jr., Walia, A. S., Lidin, B. I., Srinivas, R. V., Baskin, J. G., and Kearney, J. F. (1987). Monoclonal IgM antibodies that inhibit primary Moloney murine sarcoma growth. J. Natl. Cancer. Inst. 78, 547-556.
112. Lecomte, J., Cainelli-Gebara, V., Mercier, G., Mansour, S., Talbot, P. J., Lussier, G., and Oth, D. (1987). Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Arch. Virol. 97, 123-130.
113. Ledbetter, J., and Nowinski, R. C. (1977). Identification of the Gross cell surface antigen associated with murine leukemia virus-infected cells. J. Virol. 23, 315-322.
114. Lederman, M. M., Purvis, S. F., Walter, E. I., Carey, J. T., and Medof, M. E. (1989). Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor. Proc. Natl. Acad. Sci. USA 86, 4205-4209.
115. Lee, B., Sharron, M., Blanpain, C., Doranz, B. J., Vakili, J., Setoh, P., Berg, E., Liu, G., Guy, H. R., Durell, S. R., Parmentier, M., Nan Chang, C., Price, K., Tsang, M., and Doms, R. W. (2000). Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274, 9617-9626.
116. Lee, T. H., Essex, M., De Noronha, F., and Azocar, J. (1982). Neutralization of feline leukemia virus with feline antisera to leukocyte alloantigens. Cancer. Res. 42, 3995-3999.
117. Lefrancois, L. (1984). Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: Distinct mechanisms of action in vivo. J. Virol. 51, 208-214.
118. Lemon, S. M., and Binn, L. N. (1985). Incomplete neutralization of hepatitis A virus in vitro due to lipid-associated virions. J. Gen. Virol. 66, 2501-2505.
119. Letchworth, G. J. I., and Appleton, J. A. (1983). Passive protection of mice and sheep against bluetongue virus by a neutralizing monoclonal antibody. Infect. Immun. 39, 208-212.
120. Levine, B., Hardwick, J. M., Trapp, B. D., Crawford, T. O., Bollinger, R. C., and Griffins, D. E. (1991). Antibody mediated clearance of Sindbis encephalomyelitis in SCID mice: A novel mechanism for recovery from viral infection. FASEB J. 5 (Abstract).
121. Li, L., Coelingh, K. L., and Britt, W. J. (1995). Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein. H. J. Virol. 69, 6047-6053.
122. Liebert, U. G., Schneider-Schaulies, S., Baczko, K., and Ter Meulen, V. (1990). Antibody-induced restriction of viral gene expression in measles encephalitis in rats. J. Virol. 64, 706-713.
123. Lonberg, N., Taylor, L. D., Harding, F. A., Trounstine, M., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., Munoz-O'Regan, D., O'Donnell, S. L., Lapachet, E. S. G., Bengoechea, T., Fishwild, D. M., Carmack, C. E., Kay, R. M., and Huszar, D. (1994). Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368, 856-859.
124. Lubinski, J., Nagashunmugam, T., and Fridman, H. M. (1998). Viral interference with antibody and complement. Semin. Cell. Dev. Biol. 9, 329-337.
125. Lund, O., Hansen, J., Sørensen, A. M., Mosekilde, E., Nielsen, J. O., and Hansen, J. E. (1995). Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J. Virol. 69, 2393-2400.
126. Mandel, B. (1961). Reversibility of the reaction between poliovirus and neutralizing antibody of rabbit origin. Virology 14, 316-328.
127. Mandel, B. (1976). Neutralization of poliovirus: A hypothesis to explain the mechanism and the one-hit character of the neutralization reaction. Virology 69, 500-510.
128. Manzanec, M. B., Coudret, C. L., and Fletcher, D. R. (1995). Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. 69, 1339-1343.
129. Manzanec, M. B., Lamm, M. E., Lyn, D., Porter, A., and Bedrud, J. G. (1992). Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus. Res. 23, 1-12.
130. Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A., Nichol, S. T., Peters, C. J., Parren, P. W. H. I., and Burton, D. R. (1999). Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73, 6024-6030.
131. Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., Van Cott, T. C., Hayes, D., Louder, M. K., Brown, C., Sapan, C. V., Frankel, S. S., Lu, Y., Robb, M. L., Katinger, H., and Birx, D. L. (1999). Protection of macaques against pathogenic SHIV-89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009-4018.
132. Mascola, J. R., Mathieson, B. J., Zack, P. M., Walker, M. C., Halstead, S. B., and Burke, D. S. (1993). Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res. Hum. Retroviruses 9, 1175-1184.
133. Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., and Lewis, M. G. (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210.
134. Massey, R. J., and Schochetman, G. (1981). Viral epitopes and monoclonal antibodies: Isolation of blocking antibodies that inhibit virus neutralization. Science 213, 447-449.
135. Mathews, J. H., Roehrig, J. T., and Trent, D. W. (1985). Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J. Virol. 55, 594-600.
136. Mbow, M. L., Gilmore, R. D., Jr., and Titus, R. G. (1999). An OspC-specific monoclonal antibody passively protects mice from tick-transmitted infection by Borrelia burgdorferi B31. Infect. Immun. 67, 5470-5472.
137. McCullough, K. C., Crowther, J. R., Butcher, R. N., Carpenter, W. C., Brocchi, E., Cappucci, L., and De Simone, F. (1986). Immune protection against foot-and-mouth disease virus studied using virus neutralizing and non neutralizing concentrations of monoclonal antibodies. Immunology 58, 421-428.
138. McCullough, K. C., De Simone, F., Brocchi, E., Capucci, L., Crowther, J. R., and Kihm, U. (1992). Protective immune response against foot-and-mouth disease. J. Virol. 66, 1835-1840.
139. McCullough, K. C., Parkinson, D., and Crowther, J. R. (1988). Opsonization-enhanced phagocytosis of foot-and-mouth disease virus. Immunology 65, 187-191.
140. McIntosh, K., and Chanock, R. M. (1990). Respiratory syncytial viruses. In Fields Virology. New York: Raven Press, pp. 1045-1072.
141. McKendall, R. R. (1985). IgG-mediated viral clearance in experimental infection with herpes simplex virus type 1: Role for neutralization and Fc-dependent functions but not C′ cytolysis and C5 chemotaxis. J. Infect. Dis. 151, 464-470.
142. McLain, L., and Dimmock, N. J. (1994). Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J. Gen. Virol. 75, 1457-1460.
143. Megran, D. W., Stiver, G., Peeling, R., Maclean, I. W., and Brunham, R. C. (1988). Complement enhancement of neutralizing antibody to the structural proteins of Chlamydia trachomatis. J. Infect. Dis. 158, 661-663.
144. Merkenschlager, M., Buck, D., Beverley, P. C., and Sattentau, Q. J. (1990). Functional epitope analysis of the human CD4 molecule. The MHC class II-dependent activation of resting T cells is inhibited by monoclonal antibodies to CD4 regardless of whether or not they recognize epitopes involved in the binding of MHC class II or HIV gp120. J. Immunol. 145, 2839-2845.
145. Merz, D. C., Scheid, A., and Choppin, P. W. (1981). Immunological studies of the functions of paramyxovirus glycoproteins. Virology 109, 94-105.
146. Mester, J. C., Glorioso, J. C., and Rouse, B. T (1991). Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies. J. Infect. Dis. 163, 263-269.
147. Mochizuki, Y., de Ming, T., Hayashi, T., Itoh, M., Hotta, H., and Homma, M. (1990). Protection of mice against Sendai virus pneumonia by non-neutralizing anti-F monoclonal antibodies. Microbiol. Imunol. 34, 171-183.
148. Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., Burton, D. R., and Ho, D. D. (1995). Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69, 101-109.
149. Moore, J. P., and Ho, D. D. (1995). HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS 9 (Suppl A), S117-S136.
150. Morens, D. M., Halstead, S. B., and Marchette, N. J. (1987). Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb. Pathog. 3, 231-237.
151. Moulard, M., Lortat-Jacob, H., Mondor, I., Roca, G., Wyatt, R., Sodroski, J., Zhao, L., Olson, W., Kwong, P. D., and Sattentau, Q. J. (2000). Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74, 1948-1960.
152. Mozdzanowska, K., Furchner, M., Washko, G., Mozdzanowski, J., and Gerhard, W. (1997). A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J. Virol. 71, 4347-4355.
153. Mozdzanowska, K., Maiese, K., Furchner, M., and Gerhard, W. (1999). Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254, 138-146.
154. Murphy, B. R., Kasel, J. A., and Chanock, R. M. (1972). Association of serum anti-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. 286, 1329-1332.
155. Murphy, B. R., and Webster, R. G. (1996). Orthomyxoviruses. In Fields Virology (Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., Melnick, J. L., Monath, T. P., Roizman, B., and Straus, S. E., Eds.). Philadelphia, PA: Lippincott-Raven Publishers, pp. 1397-1446.
156. Nakanaga, K., Yamanouchi, K., and Fujiwara, K. (1986). Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice. J. Virol. 59, 168-171.
157. Oakes, J. E., and Lausch, R. N. (1981). Role of Fc fragments in antibody-mediated recovery from ocular and subcutaneous herpes simplex virus infections. Infect. Immun. 33, 109-114.
158. Old, L. J., Stockert, E., Boyse, E. A., and Geering, G. (1967). A study of passive immunization against a transplanted G+ leukemia with specific antiserum. Proc. Soc. Exp. Biol. Med. 124, 63-68.
159. Oldstone, M. B. A. (1975). Virus neutralization and virus-induced immune complex disease. Progr. Med. Virol. 19, 84-119.
160. Ollmann Saphire, E., Parren, P. W. H. I., Barbas, C. F., III, Burton, D. R., and Wilson, I. A. (2001). Crystallization and preliminary structure determination of an intact human immunoglobulin b12: An antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallogr. (in press).
161. Orentas, R. J., and Hildreth, J. E. K. (1993). Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res. Hum. Retroviruses 9, 1157-1165.
162. Pantaleo, G., Demarest, J. F., Vaccarezza, M., Graziosi, C., Bansal, G. P., Koenig, S., and Fauci, A. S. (1995). Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. Eur. J. Immunol. 25, 226-231.
163. Parren, P. W. H. I. (1992). Preparation of genetically engineered monoclonal antibodies for human immunotherapy. Hum. Antibod. Hybridomas 3, 137-145.
164. Parren, P. W. H. I., and Burton, D. R. (1997). Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards anti-viral immunotherapy. Chem. Immunol. 65, 18-56.
165. Parren, P. W. H. I., Ditzel, H. J., Gulizia, R. J., Binley, J. M., Barbas, C. F., Burton, D. R., and Mosier, D. E. (1995). Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 9, F1-F6.
166. Parren, P. W. H. I., Gauduin, M.-C., Koup, R. A., Poignard, P., Sattentau, Q. J., Fisicaro, P., and Burton, D. R. (1997a). Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Lett. 58, 125-132.
167. Parren, P. W. H. I., Maruyama, T., Burton, D. R., and Jahrling, P. B. (2001a). A human neutralizing antibody protects against challenge with Ebola Zaire in an animal model. Manuscript in preparation.
168. Parren, P. W. H. I., Marx, P., Cheng-Mayer, C., Harouse, J., Moore, J. P., and Burton, D. R. (2001b). A neutralizing human monoclonal antibody protects macaques against challenge with a pathogenic R5 SHIV Manuscript in preparation.
169. Parren, P. W. H. I., Mondor, I., Naniche, D., Ditzel, H. J., Klasse, P. J., Burton, D. R., and Sattentau, Q. J. (1998). Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72, 3512-3519.
170. Parren, P. W. H. I., Moore, J. P., Burton, D. R., and Sattentau, Q. J. (1999). The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. AIDS 13 (Suppl A), S137-S162.
171. Parren, P. W. H. I., Sattentau, Q. J., and Burton, D. R. (1997b). HIV-1 antibody-Debris or virion? Nature. Med. 3, 366-367.
172. Peeling, R. W., and Brunham, R. C. (1991). Neutralization of Chlamydia trachomatis: Kinetics and stoichiometry. Infect. Immun. 59, 2624-2630.
173. Philipson, L. (1966). Interaction betwen poliovirus and immunoglobulins. II. Basic aspects of virus-antibody interaction. Virology 28, 35-46.
174. Philipson, L., Killander, J., and Albertsson, P.-A. (1966). Interaction between poliovirus and immunoglobulins I. Detection of virus antibodies by partition in aqueous polymer phase systems. Virology 28, 22-34.
175. Pincus, S. H., Cole, R., Ireland, R., McAtee, F., Fujisawa, R., and Portis, J. (1995). Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J. Virol. 69, 7152-7158.
176. Poignard, P., Sabbe, S., Picchio, G. R., Wang, M., Gulizia, R. J., Katinger, H., Parren, P. W. H. I., Mosier, D. E., and Burton, D. R. (1999). Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10, 431-438.
177. Pollock, D. P., Kutzko, J. P., Birck-Wilson, E., Williams, J. L., Echelard, Y., and Meade, H. M. (1999). Transgenic milk as a method for the production of recombinant antibodies. J. Immunol. Meth. 231, 147-157.
178. Portis, J. L., Spangrude, G. J., and McAtee, F. J. (1994). Identification of a sequence in the unique 5′ open reading frame of the gene encoding glycosylated Gag which influences the incubation period of neurodegenerative disease induced by a murine retrovirus. J. Virol. 68, 3879-3887.
179. Possee, R. D., Schild, G. C., and Dimmock, N. J. (1982). Studies on the mechanism of neutralization of influenza virus by antibody: Evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virions transcriptase activity. J. Gen. Virol. 58, 373-386.
180. Prince, A. M. (1994). Challenges for development of hepatitis C virus vaccines. FEMS Microbiol. Rev. 14, 273-277.
181. Prince, G. A., Hemming, V. G., Horswood, R. L., Baron, P. A., and Chanock, R. M. (1987). Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J. Virol. 61, 1851-1854.
182. Prince, G. A., Hemming, V. G., Horswood, R. L., Baron, P. A., Murphy, B. R., and Chanock, R. M. (1990). Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats. J. Virol. 64, 3091-3092.
183. Prince, G. A., Hemming, V. G., Horswood, R. L., and Chanock, R. M. (1985a). Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 3, 193-206.
184. Prince, G. A., Horswood, R. L., and Chanock, R. M. (1985b). Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol. 55, 517-520.
185. Prohaszka, Z., Nemes, J., Hidvegi, T., Toth, F. C., Kerekes, K., Erdei, A., Szabo, J., Ujhelyi, E., Thielens, N., Dierich, M. R., Spath, P., Ghebrehiwet, B., Hampl, H., Kiss, J., Arlaud, G., and Fust, G. (1997). Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. AIDS 11, 949-958.
186. Rappaport, I. (1970). An analysis of the inactivation of MS2 bacteriophage with antiserum. J. Gen. Virol. 6, 25-32.
187. Raux, H., Coulon, P., Lafay, F., and Flamand, A. (1995). Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing. Virology 210, 400-408.
188. Rizzuto, C. D., and Sodroski, J. G. (1997). Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J. Virol. 71, 4847-4851.
189. Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas, C. F., and Burton, D. R. (1994). Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68, 4821-4828.
190. Robinson, W. E., Montefiori, D. C., and Mitchell, W. M. (1988). Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet, i, 790-794.
191. Roden, R. S., Weissinger, E. M., Henderson, D. W., Booy, F., Kirnbauer, R., Mushinski, J. F., Lowy, D. R., and Schiller, J. T. (1994). Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsidproteins. J. Virol. 68, 7570-7574.
192. Rosengard, A. M., Alonso, L. C., Korb, L. C., Baldwin, W. M., Sanfilippo, F., Turka, L. A., and Ahearn, J. M. (1999). Functional characterization of soluble and membrane-bound forms of vaccinia complement control protein. Mol. Immunol. 36, 685-697.
193. Rother, R. P., Rollins, S. A., Fodor, W. L., Albrecht, J. C., Setter, E., Fleckenstein, B., and Squinto, S. P. (1994). Inhibition of complement-mediated cytolysis by the terminal complement-inhibitor of herpesvirus saimiri. J. Virol. 68, 730-737.
194. Saarlos, M. N., Sullivan, B. L., Czerniewski, M. A., Parameswar, K. D., and Spear, G. T. (1997). Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1. J. Virol. 71, 1640-1643.
195. Saifuddin, M., Ghassemi, M., Patki, C., Parker, C. J., and Spear, G. T. (1994). Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res. Hum. Retroviruses 10, 829-837.
196. Saifuddin, M., Parker, C. J., Peeples, M. E., Gorny, M. K., Zolla-Pazner, S., Ghassemi, M., Rooney, I. A., Atkinson, J. P., and Spear, G. T. (1995). Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182, 501-509.
197. Sakurai, H., Williamson, R. A., Crowe, J. E., Beeler, J. A., Poignard, P., Bastidas, R. B., Chanock, R. M., and Burton, D. R. (1999). Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: Significance for subunit vaccines. J. Virol. 73, 2956-2962.
198. Sanna, P. P., De Logu, A., Williamson, R. A., Horn, Y.-L., Straus, S. E., Bloom, F. E., and Burton, D. R. (1996). Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology 215, 101-106.
199. Sanner, M. F. (1999). Python: A programming language for software integration and development. J. Mol. Graphics. Mod. 17, 57-61.
200. Sanner, M. F., Duncan, B. S., Carrillo, C. J., and Olson, A. J. (1999). Integrating computation and visualization for biomolecular analysis: An example using python and AVS. Proc. Pacific. Symp. Biocomputing 99, 401-412.
201. Sanner, M. F., Spehner, J.-C., and Olson, A. J. (1996). Reduced surface: An efficient way to compute molecular surfaces. Biopolymers 38, 305-320.
202. Sattentau, Q. J., Dalgleish, A. G., Weiss, R. A., and Beverley, P. C. (1986). Epitopes of the CD4 antigen and HIV infection. Science 234, 1120-1123.
203. Sattentau, Q. J., and Moore, J. P. (1995). Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182, 185-196.
204. Sattentau, Q. J., Zolla-Pazner, S., and Poignard, P. (1995). Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206, 713-717.
205. 2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fails to protect mice against lethal YF encephalitis. J. Gen. Virol. 76, 217-220.
206. Schmaljohn, A. L., Johnson, E. D., Dalrymple, J. M., and Cole, G. A. (1982). Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 297, 70-72.
207. Schmaljohn, A. L., Kokubun, K. M., and Cole, G. A. (1983). Protective monoclonal antibodies define maturational and pH-dependent antigenic changes in Sindbis virus E1 glycoprotein. Virology 130, 144-154.
208. Schønning, K., Lund, O., Lund, O. S., and Hansen, J. E. S. (1999). Stoichiometry of monoclonal anitbody neutralization of T-cell line-adapted human immunodeficiency virus type 1. J. Virol. 73, 8364-8370.
209. Schutten, M., Andeweg, A. C., Bosch, M. L., and Osterhaus, A. D. (1995). Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand. J. Immunol. 41, 18-22.
210. Scicluna, L. A., and McCullough, K. C. (1999). Rapidity of specific antibody-antigen interactions. Scand. J. Immunol. 50, 167-176.
211. Shibata, R., Igarashi, T., Haigwood, N., Buckler-White, A., Ogert, R., Ross, W., Willey, R., Cho, M. W., and Martin, M. A. (1999). Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5, 204-210.
212. Smith, G. L. (1999). Vaccinia virus immune evasion. Immunol. Lett. 65, 55-62.
213. Smith, T. J., Chase, E. S., Schmidt, T. J., Olson, N. H., and Baker, T. S. (1996). Neutralising antibody to human rhinovirus 14 penetrates the receptor-binding canyon. Nature 383, 350-354.
214. Smith, T. J., Olson, N. H., Cheng, R. H., Liu, H., Chase, E. S., Lee, W. M., Leippe, D. M., Mosser, A. G., Rueckert, R. R., and Baker, T. S. (1993). Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. J. Virol. 67, 1148-1158.
215. Smith, T. J. (2001). Antibody interactions with rhinovirus; lessons for mechanisms of neutralization and the role of immunity in viral evolution. Curr. Top. Microbiol. Immunol. (in press).
216. Spear, G. T., Sullivan, B. L., Landay, A. L., and Lint, T. F. (1990). Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J. Virol. 64, 5869-5873.
217. Spiller, O. B., Hanna, S. M., Devine, D. V., and Tufaro, F. (1997). Neutralization of cytomegalovirus virions: The role of complement. J. Infect. Dis. 176, 339-347.
218. Stewart, P. L., Chiu, C., Huang, S., Muir, T., Zhao, Y., Chait, B., Mathias, P., and Nemerow, G. R. (1997). Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO J. 16, 1189-1198.
219. Stewart, P. L., and Nemerow, G. R. (1997). Recent structural solutions for antibody neutralization of viruses. Trends Microbiol 5, 229-233.
220. Stoiber, H., Clivio, A., and Dierich, M. P. (1997). Role of complement in HIV infection. Annu. Rev. Immunol. 15, 649-674.
221. Stott, E. J. (1994). Towards a vaccine against AIDS: Lessons from simian immunodeficiency virus vaccines. Curr. Top. Microbiol. Immunol. 188, 221-237.
222. Stott, E. J., Bew, M. H., Taylor, G., Jebbett, J., and Collins, A. P. (1984). The characterization and uses of monoclonal antibodies to respiratory syncytial virus. Dev. Biol. Stand. 57, 237-244.
223. Sullivan, B. L., Knopoff, E. J., Saifuddin, M., Takefman, D. M., Saarloos, M.-N., Sha, B. E., and Spear, G. T. (1996). Susceptibility of HIV-1 plasma virus to complement-mediated lysis. J. Immunol. 157, 1791-1798.
224. Sullivan, B. L., Takefman, D. M., and Spear, G. T. (1998a). Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology 248, 173-181.
225. Sullivan, N., Sun, Y., Binley, J., Lee, J., Barbas, C. F., III, Parren, P. W. H. I., Burton, D. R., and Sodroski, J. (1998b). Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J. Virol. 72, 6332-6338.
226. Sullivan, N., Sun, Y., Li, J., Hofmann, W., and Sodroski, J. (1995). Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69, 4413-4422.
227. Takeda, A., Tuazon, C. U., and Ennis, F. A. (1988). Antibody-enhanced infection by HTV-1 via Fc receptor-mediated entry. Science 242, 580-583.
228. Takefman, D. M., Sullivan, B. L., Sha, B. E., and Spear, G. T. (1998). Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology 246, 370-378.
229. Taylor, H. P., Armstrong, S. J., and Dimmock, N. J. (1987). Quantitative relationships between an influenza virus and neutralizing antibody. Virology 159, 288-298.
230. Thomas, L. H., Cook, R. S., Wyld, S. G., Furze, J. M., and Taylor, G. (1998). Passive protection of gnotobiotic calves using monoclonal antibodies directed at different epitopes on the fusion protein of bovine respiratory syncytial virus. J. Infect. Dis. 177, 874-880.
231. Tortorella, D., Gewurz, B. F., Furman, M. H., Schust, D. J., and Ploegh, H. L. (2000). Viral subversion of the immune system. Annu. Rev. Immunol. 18, 861-926.
232. Truneh, A., Buck, D., Cassatt, D. R., Juszczak, R., Kassis, S., Ryu, S. E., Healey, D., Sweet, R., and Sattentau, Q. (1991). A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion. J. Biol. Chem. 266, 5942-5948.
233. Ubol, S., Levine, B., Lee, S.-H., Greenspan, N. S., and Griffin, G. E. (1995). Roles of immunoglobulin valency and the heavy-chain constant domain in antibody-medicated downregulation of sindbis virus replication in persistently infected neurons. J. Virol. 69, 1990-1993.
234. + target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J. Exp. Med. 186, 1287-1298.
235. Vanderplasschen, A., Hollinshead, M., and Smith, G. L. (1997). Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol. 78, 2041-2048.
236. Vanderplasschen, A., Matthew, E., Hollinshead, M., Sim, R. B., and Smith, G. L. (1998). Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. USA 95, 7544-7549.
237. Van Kammen, A. (1999). Beijerinck's contribution to the virus concept-An introduction. Arch. Virol. (Suppl) 15, 1-8.
238. Verma, R., Boleti, E., and George, A. J. (1998). Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Meth. 216, 165-181.
239. Vernon, S. K., Neurath, A. R., and Rubin, B. A. (1972). Electron microscopic studies on the structure of rabies virus. J. Ultrastruct. Res. 41, 29-42.
240. Virgin, H. W., IV, Bassel-Duby, R., and Fields, B. N. (1988). Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J. Virol. 62, 4594-4604.
241. Vzorov, A. N., and Compans, R. W. (2000). Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization. J. Virol. 74, 8219-8225.
242. Wallis, C., and Melnick, J. L. (1967). Virus aggregation as the cause of the non-neutralizable persistent fraction. J. Virol. 1, 478-488.
243. Wallis, C., and Melnick, J. L. (1970). Herpesvirus neutralization: Induction of the persistent fraction by insufficient antibody. Virology 42, 128-137.
244. Walsh, E. E., Schlesinger, J. J., and Brandriss, M. W. (1984). Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. 43, 756-758.
245. Webster, R. G., and Laver, W. G. (1967). Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. J. Immunol. 99, 49-55.
246. Wege, H., Dorries, R., and Wege, H. (1984). Hybridoma antibodies to the murine coronavirus JHM: Characterization of epitopes on the peplomer protein. J. Gen. Virol. 65, 1931-1942.
247. Weiland, E., Wieczorek-Krohmer, M., Kohl, D., Conzelmann, K. K., and Weiland, F. (1999). Monoclonal antibodies to GP5 of porcine reproductive and respiratory syndrome virus are more effective in virus neutralization than monoclonal antibodies to GP4. Vet. Microbiol. 66, 171-186.
248. Weiss, L., Okada, N., Haeffner-Cavaillon, N., Hattori, C., Faucher, C., Kazatchkine, M. D., and Okada, H. (1992). Decreased expression of the membrane inhibitor of complement-mediated cytolysis CD59 on T-lymphocytes of HIV-infected patients. AIDS 6, 379-385.
249. Weltzin, R., Hsu, S. A., Mittler, E. S., Georgakopoulos, K., and Monath, T. P. (1994). Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrobial Agents Chemother. 38, 2785-2791.
250. Weltzin, R., Traina-Dorge, V., Soike, K., Zhang, J. Y., Mack, P., Soman, G., Drabik, G., and Monath, T. P. (1996). Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J. Infect. Dis. 174, 256-261.
251. Westaway, E. G. (1965). The neutralization of arboviruses. I. Neutralization in homologous virus-serum mixtures with two group B arboviruses. Virology 26, 517-527.
252. Wild, F., Cathala, F., and Huppert, J. (1975-1976). Vesicular stomatitis virus (measles) pseudotypes: Tool for demonstrating defective measles infections. Intervirology 6, 185-189.
253. Wilson, J. A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A. L., and Hart, M. K. (2000). Epitopes involved in antibody-mediated protection from Ebola Virus. Science 287, 1664-1666.
254. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. (1994). Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455.
255. Wright, K. E., and Buchmeier, M. J. (1991). Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection. J. Virol. 65, 3001-3006.
256. Wu, H., Kwong, P. D., and Hendrickson, W. A. (1997). Dimeric association and segmental variability in the structure of human CD4. Nature 387, 527-530.
257. Zavada, J., and Rosenbergova, M. (1972). Phenotypic mixing of vesicular stomatitis virus with fowl plague virus. Acta Virol. 16, 103-114.
258. Zebedee, S. L., and Lamb, R. A. (1988). Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 62, 2762-2772.
259. Zeitlin, L., Whaley, K. J., Sanna, P. P., Moench, T. R., Bastidas, R., De Logu, A., Williamson, R. A., Burton, D. R., and Cone, R. A. (1996). Topically applied human recombinant monoclonal IgG antibody and its Fab and F(ab′) fragments protect mice form vaginal transmission of HSV-2. Virology 225, 213-215.